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Abstract:  114 
Background: Activated PI3-kinase delta syndrome 2 (APDS2/PASLI-R1), a recently 115 
described primary immunodeficiency, results from autosomal dominant mutations in PIK3R1, 116 
the gene encoding the regulatory subunit (p85α, p55α and p50α) of class IA PI3-kinases. 117 
Objectives: Review the clinical, immunological and histopathological phenotypes of APDS2 118 
in a genetically defined international patient cohort. 119 
Methods: The medical and biological records of 36 genetically diagnosed APDS2 patients 120 
were collected and reviewed. 121 
Results: Mutations within splice acceptor and donor sites of exon 11 of the PIK3R1 gene lead 122 
to APDS2. Recurrent upper respiratory tract infections (100%), pneumonitis (71%) and 123 
chronic lymphoproliferation (89%) (including adenopathy (75%), splenomegaly (43%) and 124 
upper respiratory tract lymphoid hyperplasia (48%)) were the most common features. Growth 125 
retardation was frequently noticed (45%). Other complications were mild neurodevelopmental 126 
delay (31%), malignant diseases (28%), most of them being B cell lymphomas, autoimmunity 127 
(17%), bronchiectasis (18%) and chronic diarrhea (24%). Decreased serum IgA and IgG 128 
(87%), increased IgM levels (58%), B cell lymphopenia (88%) associated with an increased 129 
frequency of transitional B cells (93%), decreased number of naive CD4 and naive CD8 but 130 
increased number of CD8 effector/memory T cells were predominant immunological features. 131 
The majority of patients (89%) received Ig replacement; three patients were treated with 132 
rituximab and six patients with rapamycin initiated after diagnosis of APDS2. Five patients 133 
died from APDS2-related complications.  134 
Conclusion: APDS2 is a combined immunodeficiency with variable clinical phenotype. 135 
Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation 136 
and lymphoma similar to APDS1/PASLI-CD. Ig replacement therapy, rapamycin and likely 137 
in the near future selective PI3Kδ- inhibitors are possible treatment options. 138 
 139 
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Clinical Implications: APDS2/PASLI-R1 should be screened in sporadic or autosomal-140 
dominant primary immunodeficiencies associated with lymphadenopathies, growth 141 
retardation, high IgM (HIGM-like syndrome), and B cell lymphopenia with an increased 142 
percentage of transitional B cells and decreased naïve T cells. 143 
  144 
Capsule summary: Comparison of clinical and biological records of 36 genetically 145 
diagnosed APDS2/PASLI-R1 patients highlights the severity of the disease and its variable 146 
phenotype spectrum. 147 
 148 
Key words:  149 
PID 150 
PI3K 151 
p85 alpha 152 
p110 delta 153 
APDS 154 
PASLI 155 
HIGM 156 
adenopathy 157 
immunodeficiency 158 
antibody deficiency 159 
 160 
Abbreviations: 161 
APDS: Activated PI3-kinase δ syndrome 162 
PASLI: p110δ-activating mutations causing Senescent T cells, Lymphadenopathy, and 163 
Immunodeficiency 164 
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PID: primary immunodeficiency 165 
DLBCL:  diffuse large B cell lymphoma 166 
HL: Hodgkin lymphoma 167 
CLL: Chronic lymphocytic leukaemia 168 
HLA: Human Leukocyte Antigen 169 
  170 
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Introduction: 171 
Activated PI3-kinase δ syndrome 2 (APDS2) also named p110δ-activating mutations causing 172 
Senescent T cells, Lymphadenopathy, and Immunodeficiency (PASLI-R1) [MIM# 616005] is 173 
a primary immunodeficiency (PID) resulting from autosomal dominant mutations in PIK3R1, 174 
the gene encoding the regulatory subunit (p85α, p55α and p50α) of class IA PI3-kinases (1, 175 
2). Class IA PI3K molecules are composed of a p110 catalytic subunit (p110α, p110β, or 176 
p110δ) and a regulatory subunit (p85α, p55α, p50α, p85β, or p55γ) that regulates the stability, 177 
cellular localization, and function of p110. The function of class IA PI3Ks is to convert 178 
phosphatidylinositol 4,5-bisphosphate into phosphatidylinositol 3,4,5-trisphosphate (PIP3), an 179 
important phospholipid secondary messenger. Each of the catalytic subunits can bind to any 180 
of the regulatory subunits (3). Expression of the p110δ catalytic subunit is restricted mainly to 181 
leukocytes, whereas p110α and p110β are ubiquitously expressed. The widely expressed p85α 182 
regulatory subunit is the predominant regulatory subunit in lymphocytes. Mutations in a 183 
splice donor site of PIK3R1 have been shown to cause APDS2 as a result of skipping of exon 184 
11 (coding exon 10), encoding the amino acids 434-475 of p85α. The splicing from exon 10 185 
to exon 12 is in-frame and therefore results in a shortened p85α protein; the p55α and p50α 186 
isoforms are similarly affected. The shortened p85α protein is dominantly responsible for 187 
hyper-activated PI3Kδ -signaling in T and B lymphocytes (1, 2).  188 
The main clinical and biological findings in the 13 published APDS2 patients reported so far 189 
were recurrent respiratory tract infections, lymphoproliferation and antibody deficiency (1, 2, 190 
4, 5). APDS2 resembles APDS1 also named PASLI-CD [MIM# 615513], a PID caused by 191 
autosomal-dominant, gain-of-function mutations in PIK3CD, the gene encoding the catalytic 192 
subunit p110δ, leading to hyper-activated PI3Kδ signaling in lymphocytes (6-8).  193 
In this study we reviewed the clinical, immunological and histopathological features of 194 
APDS2 in a genetically defined international cohort of 36 patients. 195 
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 196 
Patients and Methods: 197 
Genomic DNA from patients presenting with genetically undefined primary antibody 198 
deficiency were screened for mutations at the splice sites of exon 11 (coding exon 10) of the 199 
PIK3R1 gene by whole exome sequencing or targeted Sanger sequencing. Medical and 200 
biological records of 36 genetically diagnosed APDS2 patients were retrospectively collected 201 
and compared using a questionnaire. Patients treated for lymphoma and/or rituximab were 202 
excluded from the immunological analysis. The study was performed in accordance with the 203 
precepts of the Declaration of Helsinki and local ethical requirements. 204 
 205 
Results: 206 
Patient characteristics  207 
In this retrospective analysis, 36 APDS2 patients (15 males) from 31 unrelated families were 208 
included, of whom 8 patients were reported previously (1, 2). Five patients died at the age of 209 
12 (P10), 27 (P5 and P28), 30 (P11) and 36 (P20a) years, respectively (Figure 1). Alive 210 
patients had a median age of 18 years, (range from 3 to 56 years) at the time of the medical 211 
report.  212 
 213 
Genetics of heterozygous splice site mutations in PIK3R1 214 
The previously described G to A, G to C and G to T nucleotide substitutions at the +1 position 215 
of the donor splice site of PIK3R1 were identified in 42%, 29% and 13% of the patients, 216 
respectively (Figure 2). In four patients (13%) novel mutations affecting the +2 position of 217 
this donor splice site were identified, a T to A mutation; a T to G substitution, and a TG 218 
deletion. In addition, a novel mutation, a G to C nucleotide substitution, at the -1 position of 219 
the splice acceptor site of exon 11 of the PIK3R1 gene was identified (Figure 2). Exon 220 
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skipping of the exon 11 encoding the amino acids 434-475 of p85α was demonstrated by 221 
mRNA analysis for all novel mutations (Supplemental Figure 1).  222 
Ten patients were familial cases (5 families), but the large majority of patients were sporadic 223 
cases. Analysis of DNA from parents was only available for 8 patients from sporadic cases 224 
and revealed de novo mutations.  225 
 226 
Clinical presentation: 227 
Infectious complications 228 
Clinical manifestations of the 36 patients are shown in Figure 3. All presented with early 229 
onset recurrent ear, nose and throat (ENT) or broncho-pulmonary infections (median onset 1.7 230 
years of age, range from the first month of life to 10 years of age). Upper respiratory tract 231 
infections (otitis media, sinusitis) as well as lower respiratory tract infections (bronchitis and 232 
pneumonitis) were present in 100% and 77% of patients, respectively. Mild bronchial wall 233 
thickening on chest CT scan and bronchiectasis were noticed in 2 (6%) and 6 patients (18%), 234 
respectively, and bronchiectasis was diagnosed with a median age of 13 years (range 4 to 33 235 
years). The most common bacterial respiratory organisms identified were Haemophilus 236 
influenzae and Streptococcus pneumoniae. Chronic conjunctivitis reported in 7 patients 237 
progressed in 1 patient to Staphylococcus aureus-related periorbital cellulitis (P5b), and in 2 238 
patients to chronic blepharitis (P16 and P27a). Invasive bacterial infections were rare, being 239 
only reported in two cases, one patient who presented with Pseudomonas aeruginosa 240 
septicemia (P20a), and a 12-year-old boy (P10) who developed peritonitis related to 241 
infectious perforation of the small intestine leading to septic shock and death. This boy had 242 
chronic gastroenteritis associated with Campylobacter jejuni, Salmonella typhimurium and 243 
Clostridium difficile infections. Chronic cutaneo-mucosal candidiasis was observed in 3 244 
patients (P5, P25 and P28). Out of 17 patients who received Bacillus Calmette-Guerin (BCG) 245 
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vaccination, two (P21 and P26) presented with persistent local skin lesions at the vaccination 246 
site. Persistent detection of virus was reported in 36% patients with Cytomegalovirus (CMV) 247 
and Epstein-Barr virus (EBV) as the most common. Disseminated lymphadenitis associated 248 
with CMV infection was reported in 2 patients, and asymptomatic chronic CMV viremia was 249 
detected in 6 patients (17%). Chronic EBV viremia was detected in 8 patients (22%); reported 250 
in 4 patients in combination with EBV-associated lymphoproliferative disease and in 4 251 
patients as asymptomatic chronic EBV viremia. Severe varicella zoster virus (VZV) 252 
infections requiring hospitalization occurred in 2 patients (P21 and P26). One patient 253 
developed hydrocephalus following measles meningitis (P22). Two patients presented with 254 
localized molluscum contagiosum (P17 and P27a) and 1 patient with warts (P22) indicating 255 
pox virus and papilloma virus infections, respectively. Chronic viral hepatitis was reported in 256 
three patients, related to either hepatitis B (P11, P20a) or C (P5) virus infection. Except 257 
chronic Giardia intestinalis in one patient (P5), and ocular toxoplasmosis in another (P20a) 258 
no other parasitic infections were reported in our patient cohort. 259 
 260 
Lymphoproliferation 261 
Thirty-two of 36 patients (89%) showed persistent (>6 months) benign lymphoproliferation 262 
either as chronic lymphadenopathy, splenomegaly, ENT or gut infiltration (Figure 3). 263 
Lymphadenopathy and splenomegaly typically began in childhood. Lymphadenopathies 264 
mentioned in 75% of the patients were variable in size, from mild (1-3cm) in 18 of 36 of 265 
patients (50%) to large in 9 patients (25%) (3-5cm, n=7; >5 cm, n=2). 15 patients (43%) 266 
developed splenomegaly of variable size (Figure 3). Hepatomegaly developed in 8 patients 267 
(22%). Nodular lymphoid infiltration of the gut was reported in 8 patients (24%) and was 268 
associated with chronic diarrhea and/or malabsorption. Severity of ENT infiltration was 269 
variable, ranging from ENT chronic lymphoid hyperplasia without the need for surgical 270 
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interventions in 3 patients (11%), to adenoidectomies and/or tonsillectomy in 7 patients (26%) 271 
and to multiple surgical resections in 3 patients. One 6-year-old patient required multiple 272 
surgical interventions, including maxillary antrostomies, multiple adenoidectomies, 273 
tonsillectomies and reductions of basilingual tonsils. The patient subsequently developed 274 
postoperative pharyngeal stenosis, requiring 3 endoscopic dilations, which were inefficient 275 
leading to tracheotomy.  276 
Tonsil biopsies from P1 and P2 were available. As shown in Figure 4 and Supplemental 277 
Figure 2 (both presented identical abnormalities as compared to age-matched controls):  278 
prominent T cell hyperplasia and small B cell follicles were noticed. Germinal centers were 279 
small and ill-defined, with very few IgD-positive mantle cells. Large B cells in the 280 
interfollicular area were numerous and IgM-positive cells that are usually localized in 281 
germinal centres were scattered within the T cell zone. In addition, an important hyperplasia 282 
of PD1-positive T cells was present both in germinal centre and in extrafollicular areas. The 283 
frequency of scattered EBV- and/or CMV-positive cells present in the patients' biopsies were 284 
comparable to those observed in control biopsies and not consistent with EBV- and/or CMV- 285 
driven pathologies. 286 
 287 
Lymphoma 288 
Ten patients (28%) developed malignant diseases (Table 1 and Figure 1B) at a median age of 289 
onset of 23 years (6 to 40 years). The cumulative risk of developing lymphoid malignancy at 290 
the age of 40 years was calculated to be 78% (Figure 1B). Classical Hodgkin Lymphoma 291 
(CHL) was diagnosed in 5 patients (14%). Diffuse large B cell lymphoma (DLBCL) was 292 
diagnosed in 4 patients (11%) and marginal zone B cell lymphoma in 2 patients (6%). Three 293 
patients developed multiple lymphomas. One patient (P12) firstly developed at the age of 14 294 
years a nodular sclerosis CHL, treated by chemotherapy and at the age of 27 years a DLBCL, 295 
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treated by intensive chemotherapy and autologous hematopoietic stem cell transplantation 296 
(HSCT). Another patient (P20a) had 2 EBV-positive nodular sclerosis CHL at 14 and 35 297 
years of age and a marginal zone B cell lymphoma at 19 years of age. Her brother (P20b) 298 
presented also with CHL when he was 8 years old. Overall, 4 patients died of lymphoma at 299 
the ages of 27 (P5 and P28; DLBCL), 30 (P11; CHL) and 36 (P20a; CHL) years, respectively. 300 
Chronic lymphocytic leukaemia (CLL) developed in one patient (P27a) at 40 years of age. No 301 
other malignancy has been reported, except a papillary neoplasm in both breasts in a female 302 
patient.  303 
 304 
Autoimmunity and immune dysregulation 305 
Six patients (17%) developed autoimmune complications. Two patients had 306 
thrombocytopenic purpura during childhood. One patient developed autoimmune hemolytic 307 
anemia post chemotherapy for lymphoma and one patient developed Evans syndrome 308 
associated with CLL. An insulin-dependent diabetes was diagnosed in one patient. Two 309 
suffered from chronic arthritis, and one patient developed autoimmune hepatitis. In addition, 310 
three patients presented with chronic eczema. 311 
 312 
Immunological features: 313 
The patients’ main immunological characteristics are summarized in Figure 5A-H 314 
(Immunological data for individual patients are provided in Online Repository tables E1-4). 315 
The majority of patients presented with decreased serum IgG and IgA levels before onset of 316 
Ig replacement therapy (87%). Increased IgM levels were observed in most patients (58%) but 317 
not all since 26% presented with a normal level and 16% with a decreased level, before any 318 
treatment. IgM levels decreased in 5 patients and increased in 2 patients over 2-12 years after 319 
onset of Ig replacement therapy. One patient (P3a) had increased IgG and IgM but decreased 320 
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IgA levels; one (P28) had low IgA but normal IgG and IgM levels and one (P4a) had 321 
increased IgA, decreased IgG and normal IgM levels.  322 
The majority of patients (88%) presented with B cell lymphopenia worsening within 1 to 19 323 
years (Figure 5D and Supplemental Figure 3). Transitional B cells were increased in 324 
frequency in 14 out of 15 patients (93%) who had a suitable number of CD19-positive cells 325 
for analysis. Total CD3 T cell counts were normal in 74% of patients (Supplemental Figure 326 
4), CD4 T cell counts were normal in 67% of patients while CD8 T cell counts were increased 327 
in 52% of patients and remained stable over time. An inverted CD4/CD8 ratio (<1.0) was 328 
found in 82% of patients. When extended naive/memory T cell phenotype analysis was 329 
performed, the increased CD8 T cell number appeared as resulting from expanded CD8 T 330 
cells population with an effector/memory phenotype. Nearly all patients analyzed presented 331 
with a low number of naive CD4 T cells (CD31+CD45RA+/CD4+; 71% of patients) and 332 
naive CD8 T cells (CCR7+CD45RA+/CD8+; 100% of patients) worsening over time (Figure 333 
5F, G and Supplemental Figure 5A, B).  334 
 335 
Non-immunological features 336 
 337 
Growth impairment (-2SD of height) was found in 14 out of 31 patients (45%), a feature not 338 
always related to chronic diarrhea since it was absent in 9 of them. Height and weight were 339 
similarly affected since body mass index was within the normal range in all but 2 patients 340 
(min = -2.8 SD; max = +3.3 SD; median = -0.7 SD). Microcephaly was reported in 2 patients. 341 
Neurodevelopmental delay presented as mild cognitive impairment or learning disabilities 342 
was reported in 9 patients (31%). For one patient, extensibility of joints and increased glucose 343 
levels in the blood were also reported. Liver cysts and polycystic kidneys were reported in 344 
one patient each. 345 
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 346 
Treatment 347 
Twenty-two patients received various antibiotic prophylaxis (trimethoprim/sulfamethoxazole 348 
or azithromycin). The majority of patients (89%) received Ig replacement therapy (median 349 
age at onset of treatment 5 years; range 1 to 35 years). Five patients were treated with steroids 350 
because of autoimmune cytopenia (n= 2) or lymphoproliferation (n= 3). Three patients were 351 
treated with rituximab to treat lymphoproliferation (n= 2) or autoimmune hemolytic anemia 352 
(n= 1). Three patients were splenectomized, two for autoimmune cytopenia and one as a 353 
diagnostic procedure of massive splenomegaly. Immunosuppressive drugs for digestive tract 354 
disease were given in 3 patients in different combination (azathioprine, mycophenolate 355 
mofetil, methotrexate and infliximab). Episodes of lymphomas were treated conventionally 356 
with chemotherapy associated in some cases with radiotherapy and in three patients with 357 
autologous HSCT. Allogeneic HSCT from a HLA matched (10/10) unrelated donor was 358 
performed in one patient (P27b) because of molecular diagnosis, recurrent infections and the 359 
family history. The conditioning regimen consisted in treosulfan 42 g/m2, fludarabine 150 360 
mg/m2 and alamtuzumab. Five months post HSCT he was alive and well with 100% donor 361 
chimerism and no sign of GVHD. Since the diagnosis of APDS2, 6 patients were started on 362 
rapamycin treatment. The time of follow up after onset of rapamycin treatment was too short 363 
to evaluate treatment efficacy for 4 patients. Two APDS2 patients were doing well on 364 
rapamycin treatment. For both patients significant reduction of lymphoproliferation was 365 
reported.  366 
 367 
Discussion 368 
Our retrospective analysis comparing clinical features of APDS2/PASLI-R1 patients 369 
indicated a highly heterogeneous clinical phenotype with recurrent ENT and broncho-370 
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pulmonary infections during early childhood as the most common clinical manifestation. 371 
Chronic benign lymphoproliferative complications with various degrees of severity 372 
manifesting as adenopathies, spleno- or hepatomegaly were observed. Persistent EBV and/or 373 
CMV viremia were detected in several patients, indicating impaired control of viral 374 
infections. Predominant biological parameters included HIGM features, B cell lymphopenia 375 
associated with increased frequency of transitional B cells, decreased naive CD4 and CD8 T 376 
cell numbers and increased cell number and frequency of CD8 effector/memory T cells. B 377 
cell lymphoma, especially CHL, DLBCL and marginal zone B cell lymphoma were 378 
frequently reported in our cohort, indicating the oncogenic character of these PIK3R1 splice-379 
site mutations. Non-infectious and immunological manifestations noted in our APDS2 cohort 380 
of patients were growth retardation and mild neurodevelopmental delay.  381 
 382 
Overall our work underscores the conclusion that APDS2 shares similarities with APDS1. 383 
Both syndromes present a predominant antibody deficiency frequently presented as an hyper-384 
IgM like syndrome associated to a progressive B and naive T cell lymphopenia and massive 385 
lymphoproliferation. The phenotypic heterogeneity of APDS2 patients, similar to that 386 
observed in APDS1, may be related to the patient’s history of infections, environmental 387 
factors, and/or the presence of modifier genes.  388 
However, in contrast to APDS1 (Coulter et al., submitted), histological analysis revealed in 389 
the two available tonsil biopsies a reduced size of germinal centers. Although we cannot 390 
exclude that this observation could be due to the heterogeneous spectrum of the disease since 391 
only a limited number of biopsies were available, it might suggest that deletion of exon 11 of 392 
the PIK3R1 gene affects not only p110δ but other catalytic subunits of class IA PI3Ks.  393 
Increased or normal IgM together with decreased IgG and IgA serum levels and B cell 394 
lymphopenia associated with increased frequency of transitional B cells were frequently 395 
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observed in APDS2 patients and can be explained by an intrinsic B cell defect leading to 396 
enhanced differentiation of APDS2 B lymphocytes into short-lived IgM producing 397 
plasmablasts as reported for PTEN deficient murine B cells (17). Our histological analysis 398 
identifying numerous large IgM positive B cells located in the interfollicular area further 399 
supports this hypothesis. Moreover, our histological analysis indicated that hyperactive PI3K 400 
signalling interferes with the germinal centre structure likely inhibiting Ig class switch 401 
recombination. Impaired Ig class switch recombination as a cause of disturbed germinal 402 
centre architecture was indeed recently described in a murine model analysing hyperactive 403 
PI3K signalling in germinal centre B lymphocytes (18). The B cell lymphopenia in the blood 404 
of APDS2 patients could be explained by disturbed migration since B cells are proliferating in 405 
the lymphnodes as indicated by our histological analysis. 406 
The major complication of APDS2 patients (as well as of APDS1 patients) is the development 407 
of B cell lymphoma (9/36; 25%) (8, 9). Predisposition of APDS2 (as for APDS1) to B-cell 408 
lymphomagenesis could be due to several immunological abnormalities, such as a defective 409 
T-cell–mediated immune surveillance or uncontrolled B cell activation and proliferation or 410 
both. As the histopathological analysis indicated an important hyperplasia of PD1-positive T 411 
cells, aberrant TFH cell function could be considered as an additional factor for promoting 412 
survival of neoplastic B cells, as previously suggested for TFH cells present within the 413 
microenvironment of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and 414 
follicular lymphoma (FL)(10). Oncogenic potential of PIK3R1 mutations have been 415 
previously suggested by the presence of somatic mutations in PIK3R1 in Burkitt Lymphomas 416 
(11) and in endometrioid and colon cancers (12) affecting the amino acid residues 437-475, 417 
encoded by exon 11 (coding exon 10) of the PIK3R1 gene. Moreover, in the somatic 418 
mutations in cancer (COSMIC) project, mutations affecting the + 1 position (G to A and G to 419 
T) and +2 position (T to C and T to G) at the same splice-acceptor site of the PIK3R1 gene 420 
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found mutated in APDS2 have been recently annotated, a strong argument in favor of the 421 
oncogenic character of these APDS2 splice-site mutations. These somatic mutations were 422 
found in carcinoma located in ovary, large intestine, stomach and malignant melanoma 423 
underlining the possible oncogenic potential of those mutations not only for B cell lymphoma 424 
but for other cell types, suggesting an impairment of the PIK3R1 gene encoded regulatory 425 
subunits not only on p110δ (PI3Kδ) activity. Growth impairment, extensibility of joints and 426 
increased glucose levels in the blood reported for one patient might reflect deregulated p110α 427 
(and/or p110β) activity. More research will be needed to characterize possible effects of the 428 
mutant p85α∆434-475 protein on the different catalytic p110 subunits in other cells (non-429 
lymphoid lineage cells) which could be hidden by the predominant immunological phenotype.   430 
Of note, heterozygous non-synonymous germline mutations located especially within the C-431 
terminal part of p85α (downstream of amino acid 475) result in a rare autosomal dominant 432 
multisystem disease called SHORT syndrome described to be due to loss of PI3K-activity 433 
(13-15). SHORT syndrome patients present with short stature (S), hyperextensibility of joints 434 
or hernia (inguinal) or both (H), ocular depression (O), Rieger anomaly (R), and teething 435 
delay (T).  436 
Allogeneic HSCT for APDS2 was recently reported for one case (5). Herein we describe a 437 
second successful case similarly to the 8 of 11 successful cases of allogeneic HSCT for 438 
APDS1 (Coulter et al., submitted). Thus allogeneic HSCT appears to be a treatment option for 439 
severely affected APDS2, especially in the light of the increased risk of lymphoma 440 
development (Table 1 and Figure 1B), although no prognostic marker for the development of 441 
lymphoma has been identified so far.  442 
Most patients have received Ig replacement therapy since infancy to reduce the infection 443 
incidence. Since the diagnosis of APDS2, six patients were started on long-term rapamycin 444 
treatment based on the knowledge that the serine/threonine kinase mammalian target of 445 
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rapamycin (mTOR) is activated by PI3K signaling, and rapamycin treatment was reported to 446 
be beneficial in APDS1 patients ((7) and personal observation).  For two APDS2 patients in 447 
our cohort rapamycin treatment was beneficial. For one patient treatment led to disappearance 448 
of chronic conjunctivitis and normalization of tonsil size and for the other patient to reduced 449 
lymph node, liver and spleen sizes; however, the impact of this treatment on lymphocyte cell 450 
numbers and antibody titers and over a longer time period has to be further investigated. 451 
Evaluation of the efficacy of rapamycin treatment on the other APDS2 patients in our cohort 452 
was not possible due to the short treatment period. Although continuous rapamycin treatment 453 
might turn out to be very beneficial for APDS2 patients, it bears the risk of unwanted side-454 
effects outside the immune system (16). Since the hyper-activated PI3K signaling in APDS2 455 
lymphocytes is mediated by the catalytic p110δ-subunit (1, 2), treatment with p110δ-specific 456 
inhibitor could offer a new treatment prospective with possibly higher efficiency and less 457 
unwanted side-effects.  458 
Overall our study indicates that the splice-donor and splice-acceptor sites of the exon 11 459 
(coding exon 10) of the PIK3R1 gene should be sequenced in sporadic or autosomal-dominant 460 
primary immunodeficiencies associated with lymphadenopathies, growth retardation, 461 
antibody deficiency, especially HIGM, B cell lymphopenia with an increased percentage of 462 
transitional B cells as well as naïve CD4 and naïve CD8 T cell lymphopenia. 463 
Finally, our study also indicates the need for further prospective, large-cohort studies of 464 
APDS2 in order to identify clinical or laboratory biomarkers that predict disease severity and 465 
to document the impact of different treatment options.  466 
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Figure Legends 530 
 531 
Figure 1. Overall survival and lymphoma-free living of APDS2 patients.  532 
A) Overall survival of APDS2 patients from the cohort. (B) Cumulative risk of developing 533 
lymphoma according to age: the time of lymphoma-free life in APDS2 patients is herein 534 
depicted.  535 
 536 
Figure 2. Confirmed heterozygous mutations in the PIK3R1 gene of APDS2 patients. 537 
Frequency and number of patients carrying indicated mutations are presented. Mutations 538 
present in several patients from one family were counted as one mutation. 539 
 540 
Figure 3. Main clinical characteristics of APDS2 cohort. 541 
Shown is the percentage of patients, which presented with indicated clinical features. ENT: 542 
ear, nose throat; neurodev. delay: neurodevelopmental delay. 543 
 544 
 Figure 4. Main clinical complications and biological features of APDS2 patients.  545 
A) Clinical features of APDS2 patients. B) Biological features. * median age at medical 546 
report of alive patients, red: affected; light yellow: unaffected and boxes with a diagonal: 547 
unknown. C) Variability of lymphoproliferation; light yellow: unaffected and boxes with a 548 
diagonal: unknown; dark yellow: ENT chronic lymphoid hyperplasia without the need of 549 
surgical interventions, lymphadenopathies with lymph node sizes from 1-3cm; orange: 550 
adenoidectomies and/or tonsillectomy, lymph node sizes from 3-5cm; red: multiple surgical 551 
resections, lymph node sizes larger than 5 cm.  Splenomegaly was graded by its size: light 552 
yellow if it was not present, dark yellow up to half distance between coastal margin and 553 
ombilicus, dark orange up to ombilicus, or red above ombilicus. 554 
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 555 
Figure 5. Histological features of APDS2 patient's tonsil biopsies. 556 
A to E: APDS2 patient. A’ to E’: Control. All pictures are at the same magnification: x10; 557 
GC: germinal centre, MZ: mantle zone. B-cell Follicles are small (A: follicles defined by 558 
circles, B, C, D) with a few CD20+ B-cells (inset CD20 staining A) compared to control 559 
(Inset CD20 staining A’) and associated with prominent CD3+ T-cell hyperplasia (B and B’, 560 
anti-CD3 staining) compared to control. PD1 staining underlines the important hyperplasia of 561 
germinal centre- and extrafollicular-PD1+ T-cell (C) compared to control (C’). Germinal 562 
centres are ill-defined (A, B, C) and IgM+ cells usually localized in the germinal centre (D’, 563 
control) are scattered in the T-cell zone (D). Only few residual IgD+ mantle cell zone cells are 564 
present (E) compared to control (E’). 565 
 566 
Figure 6. Immunological features of APDS2 patients. 567 
A) IgG, B) IgA and C) IgM level and D) B cell number of APDS2 patients before onset of Ig 568 
replacement or other therapies. E) CD4 F) CD4 naive, G) CD8, H) CD8 naive T cell subsets 569 
of APDS2 patients.  E) and G) before onset of Ig replacement or other therapies and F) and H) 570 
at last evaluation. Solid line: lower reference value; dashed line: upper reference value. 571 
 572 
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Table 1 : Malignant diseases 1 
 2 
Patients Age at PID 
diagnostic (yrs) 
Age at onset of 
cancer (yrs) 
Type of cancer Dead/ Alive 
P5 4 25 DLBCL Dead 
P11 22 30 CHL Dead 
P12 Infancy 14/27 CHL/DLBCL Alive 
P19 9 6/11 DLBCL/MALT Alive 
P20a 36 14/19/35 CHL/MZL/CHL Dead 
P20b 8 8 CHL Alive 
P22 6 30 Breast papillary 
neoplasm 
Alive 
P23b Infancy 37 CHL Alive 
P27a 31 40 CLL Alive 
P28 5 22 DLBCL Dead 
DLBCL : Diffuse large B cell Lymphoma; CHL: Classical Hodgkin Lymphoma; MALT: Mucosa-associated 3 
lymphoid tissue Lymphoma;  CLL: Chronic Lymphocytic Leukaemia; MZL: Marginal zone B cell Lymphoma  4 
 5 
 6 
 7 
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T>G;  
n=1 (3%) 
T>A; 
 n=2 (6%) 
TG deletion;  
n=1  (3%) 
GTGAGTTTTC PIK3R1 TTTCTAG 
G>C; 
 n=1 (3%) 
G>A  
n=13 (42%) 
G>C 
n=9 (29%) 
G>T 
n=4 (13%) 
Exon 11 
(coding Exon 10) 
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A) Clinical features of APDS2 patients 
Patient % 1 2 3 a 3b 4 a 4b 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20a 20b 21 22 23a 23b 24 25 26 27a 27b 28 29 30 31
Age at medical report (yrs) 18* 13 7 37 5 56 19 27 26 20 6 11 12 30 35 19 16 34 9 11 14 18 36 26 7 34 18 44 18 8 4 46 16 27 10 3 22
Upper respiratory infections 100
Pneumonia 71
Bronchiectasis 18
Autoimmunity 17
Chronic diarrhea 24
Adenopathy 75
Splenomegaly 43
Malignant disease 28
Neurodevelopmental delay 31
Growth retardation 45
Dead 14
B) Biological features  
Patient % 1 2 3 a 3b 4 a 4b 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20a 20b 21 22 23a 23b 24 25 26 27a 27b 28 29 30 31
Increased IgM 58
Decreased IgA/IgG 87
EBV chronic replication 22
CMV chronic replication 17
Inverted ratio CD4/CD8 82
C) variability of lymphoproliferation 
Patient 1 2 3 a 3b 4 a 4b 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20a 20b 21 22 23a 23b 24 25 26 27a 27b 28 29 30 31
ENT  lymphoid hyperplasia 
Splenomegaly
Adenopathy
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Table E1. B lymphocyte subsets and Ig serum levels at initial assessment 
 
Patient Age 
(yrs) 
IgG 
(g/L) 
IgA 
(g/L) 
IgM 
(g/L) 
CD19+ 
(/µL) 
CD19+/
CD21+ 
CD24++ 
(%) 
CD19+/ 
CD38+ 
IgM+ 
(%) 
Memory 
B cells 
(%) 
Switched 
memory 
B cells 
(%) 
MZB 
cells 
(%) 
P1 1 2.2 0.23 3.3     11  
P2 2.5 0.07 0.06 3.67 162 26  8 25 45 
P3a 34 22 0.05 2.26       
P3b 2.5 0 0 2.89 224   8 41  
P4a NA          
P4b 5.5 3.64 <0.07 1.66 144      
P5 4 1.2 0 0 0      
P6 6 0.2 0.03 1.5 20      
P7 NA          
P8 5.1 1.4 0.07 2.7 120   11 5 6 
P9 3.8 0.33 0.07 6.6 60   37 26 11 
P10 1.3 0.2 0.1 1.44 192      
P11 NA          
P12 NA          
P13 12 5.64 0.09 2.38       
P14 6 4.6 0.1 1.05 277      
P15 24 1.75 0.254 8.87 48      
P16 9 2.8 0 > 2.8 100      
P17 10.5 4.5 0.06 9.35 233      
P18 4.5 3.68 0.1 4.68       
P19 17 3.37 0 2.19    2.5 5.1  
P20a NA          
P20b 8 3.5 0 0.15       
P21 7 0.16 0.25 1.15       
P22 NA          
P23a NA          
P23b NA          
P24 NA          
P25 4.9 0.24 0.01 0.14 0.52      
P26 4.6 5.79 1.81 5.42 149  15.24 2.3 1.3 0.2 
P27a 31.6 5.09 0.06 2.62 250      
P27b 3 0.1 0.06 10       
P28 5.2 9.34 0.06 0.55 180      
P29 5 0.9 0.07 1.16 228  65.8 0.8 0.5 0.3 
P30 1 2.38 0.04 3.06 107 70.1  9.2  3.9 
P31 18 4.7 0.1 2.3 55   14 0.0  
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Table E2. B lymphocyte subsets and Ig serum levels at later assessment 
 
Patient Age 
(yrs) 
IgG 
(g/L) 
IgA 
(g/L) 
IgM 
(g/L) 
CD19+ 
(/µL) 
CD19/ 
CD21+ 
CD24++ 
(%) 
CD19+ / 
CD38++ 
IgM++ 
(%) 
Memory 
B cells  
(%) 
Switched 
memory B 
cells (%) 
MZB 
cells 
(%) 
Treatment 
with 
Rituximab  
P1 12 16.97 
(s) 
0.11 1.91 108 11 12 22 13 2 7.5 years post 
rituximab 
P2 5.5 14.6 
(s) 
0.05 1.73 105 39 39 8 3 2   
P3a 34.6 22 (s) 0.05 2.26 119 11   64.5 42 34   
P3b 4 8.28 
(s) 
0.05 4.81 120 33 31 9 6 2   
P4a 55 5.3 4.27 1.43 64   2 39 22 17   
P4b 18.5 0.3 0.04 10.63 58   5 50 45 13   
P5 26* 5 (s) 0 0 0             
P6 25 9.27 
(s) 
0.04 0.04 10             
P7 22       38     14       
P8 6 6.84 
(s) 
    95   23 14 7 4   
P9 11 9.06 
(s) 
0.07 2.81 30     21 12 9   
P10 NA                     
P11 25 0.03 0.05 0.42               
P12 NA                     
P13 18 10.08 
(s) 
0.05 5 81 50.8   25.5 18.6 6.9   
P14 16.5 5.68 
(s) 
0.1 0.1 74             
P15 NA                     
P16 9.5 5.97 
(s) 
0 0.77 54 9.2 42 27 19 9.1   
P17 11 8.7 (s) 0.06 10.5 160 19.2 45.7 8.5 3.1 4.2   
P18 13 11.26 
(s) 
0.05 1.85 19 20   18 93     
P19 27           9.23 2.5 50 33.3   
P20a NA                     
P20b 26*** 5.8 (s) 0 0.16 0             
P21 7.2 0.16 0.25 1.15 64 40 37 0.6 0.6 3   
P22 33.7$ 15.11 
(s) 
0.05 16.46 122             
P23a 16 9.5 (s) 0 0 0           1 year post 
rituximab 
P23b NA                     
P24 14    13.8             
P25 6.1 4.45 
(s) 
0.13 0.003               
P26 4.6 5.79 1.81 5.42 149   15.24  2.29 1.3 0.2   
P27a 44.4$ 10.3 
(s) 
0.06 0.19 1             
P27b 15 7 (s) 0.06 0.05 32     15 2 12   
P28 25* 16.3 
(s) 
0.06 0.42 33 68   28 9.8 13.7 2 years post 
rituximab 
P29 9 13 (s) 0.06 0.63     40.5   1.9 4.3   
P30 2.2           9.23 2.5 50 33.33   
P31 NA                     
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*<2 years after post chemotherapy; ** > 10 years after chemotherapy and radiotherapy for 
HL; *** > 10 years after chemotherapy for lymphoma; $ on immunosupressive drugs; (s) on 
immunoglobulin replacement 
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Table E3. T lymphocyte subsets at initial assessment 
 
Patients Age  
(yrs) 
CD3+ 
(/µL) 
CD4+ 
(/µL) 
CD8+ 
(/µL) 
CD16+CD56+ 
(/µl) 
P1 1     
P2 2.5 1512 432 576 126 
P3a 34 1394 833 476  
P3b 2.5 2688 928 1600 224 
P4a NA     
P4b 5.5 1878 771 953 285 
P5 4 400 100 300 100 
P6 6 2500 1000 1400 350 
P7 15.5 2035 496 1251  
P8 5.1 2160 730 1020 350 
P9 3.8 2210 660 1320 120 
P10 1.3 4363 2349 1630 288 
P11 NA     
P12 NA     
P13 12     
P14 6 1793 861 780 633 
P15 24 2560 482 1850 134 
P16 9 2350 870 1330 190 
P17 10.5 2100 470 1363 2350 
P18 4.5 1900 779 741  
P19 17     
P20a 36     
P20b NA     
P21 NA     
P22 6     
P23a 16 2661 2233 942 430 
P23b NA     
P24 NA     
P25 4.9 1144 195 789 115 
P26 4.6 5357 1243 3868 764 
P27a 31.6 1200 880 550 210 
P27b NA     
P28 5.2 1580 730 950 200 
P29 5 2187 696 1439 285 
P30 1 2769 781 1687 835 
P31 18 1800 400 1380 320 
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Table E4. T lymphocyte subsets at later assessment 
 
Age 
(yrs) 
CD3+ 
(/µL) 
CD4+ 
(/µL) 
Naive CD4 
CD31+ 
CD45RA/
CD4+ (%) 
Naive CD4 
CD31+ 
CD45RA/
CD4+(/µL) 
CD8+ 
(/µL) 
Naive CD8 
CCR7+ 
CD45RA+
/CD8+(%) 
Naive CD8 
CCR7+ 
CD45RA+/
CD8+(/µL) 
CD16+ 
CD56+  
(/µL) 
Senescent 
T cell (%) 
12 1440 540 7 38 702 1 7   19.5 
5.5 957 330 20 66 341 14 48 55 16 
34.6 1394 833 4 33 476 4 19 187 16.3 
4 3432 780     2457   25 156 8.89 
55 764 420 24 103 337     356   
18.5 2107 617 7 42 1330 5 63 138   
26* 280 20 0 0 260     20   
25 1940 770     1140     240   
22 1714 452 5 23 1036 4 41 132 23.4 
6 11558 513 17 87 760 2 15 228 21.3 
11 1440 530 22 140 750     30   
NA                   
25   650     1400         
NA                   
18 704 200 8.5 17 415     1031   
16.5 2067 886     1187     14   
NA                   
9.5 2155 488 3.2 12 1384     56   
11 2930 530 4.7 25 2390     1650   
13 2040 1032 30 310 888 7 62 312 26.4 
NA                   
36** 3015 385 4 16 2554 1 23 157   
26*** 2600 400 0.5 2 2200 0 0 100   
7.2 1312 432 31 135 512 7 37     
33.7$ 4488 1079     3210         
16 2233 942     1318     430   
NA                   
14 1242 869     276       
NA                   
4.6 5357 1243 29 363 3868     764   
44.4$ 455 228     218     6   
15 965 297 35 103 619     283   
25* 3302 404     2898     370   
9 3839 2614 13 347 1225     124   
NA                   
NA                   
 
*<2 years after post chemotherapy; ** > 10 years after chemotherapy and radiotherapy for 
HL; *** > 10 years after chemotherapy for lymphoma; $ on immunosupressive drugs; (s) on 
immunoglobulin replacement 
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 1 
Clinical and immunological phenotype associated with activated PI3-kinase delta 1 
syndrome 2 (APDS2 / PASLI-R1) - A cohort study 2 
Online repository Materials 3 
Supplemental Figure 1. Novel splice acceptor and splice donor mutation at exon 11 4 
(coding exon 10) of the PIK3R1 gene lead to exon skipping. 5 
A) RT-PCRs with primers flanking exon 11 of the PIK3R1 gene with RNA extracted from 6 
patients (P19: PBLs; P8: fibroblasts and P10: T cell blasts) and healthy individuals (control 7 
1,2,3: PBLs; control 4: fibroblasts; control 5: T cell blasts). P19: de novo mutation at splice 8 
acceptor site (GRCh38; NM181523.2; C.1300 -1 position; G to C); P8: de novo mutation at 9 
splice donor site (GRCh38; NM181523.2; C.1425 +2 position T to G) and P10: 2 nt deletion 10 
at splice donor site (GRCh38; NM181523.2; C.1425 +2,3 position; TG deletion). 11 
B) Sequencing chromatogram showing the skipping of exon 11 (coding exon 10). Sequencing 12 
was performed with PCR products amplified from cDNA from P28. P28: de novo mutation at 13 
splice donor site (GRCh38; NM181523.2; C.1425 +2 position T to A). 14 
 15 
Supplemental Figure 2. Large B-cells in the interfollicular area are in cycle. 16 
APDS2 patient's tonsils histology showed numerous Ki67 positive cells outside the positive 17 
germinal centre (A x10) in comparison to a control (A' x10). Double staining (B, CD20: 18 
brown, Ki67: red; x40) showed that large B-cells in the interfollicular area were in cycle.  19 
 20 
Supplemental Figure 3. B cell counts over time. 21 
Every single symbol represents an APDS2 patient. Solid line: lower reference value. 22 
 23 
Supplemental Figure 4. CD3 T cell counts.  24 
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 2 
T cell counts before onset of any therapies. Solid line: lower reference value; dashed line: 25 
upper reference value. 26 
 27 
Supplemental Figure 5. Development of naive T cell numbers over time.  28 
Numbers of naive CD4 (A) and naive CD8 (B) T cells. Every single symbol represents an 29 
APDS2 patient. Solid line: lower reference value. 30 
 31 
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